Switzerland first to pass European Commission's GMP equivalence test for drug APIs
This article was originally published in SRA
Executive Summary
Switzerland has become the first country to receive an "equivalence" rating from the European Commission for its regulatory framework on active pharmaceutical ingredients (APIs)1,2. This means that the country will not have to confirm in writing that individual consignments of Swiss-manufactured APIs imported into the EU match up to the latter's good manufacturing practice standards.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.